Protego Biopharma, founded in 2011 and headquartered in San Diego, California, is dedicated to developing therapeutics that leverage clear human genetic links. The company's core mission is to create safe and effective treatments for protein misfolding diseases. Their product lineup includes Tafamidis, a disease-modifying agent. Protego Biopharma focuses on drug discovery and development, utilizing genetic evidence and bioinformatics to target specific protein misfolding disorders.
Notable figures affiliated with Protego Biopharma include leading scientists and biotech entrepreneurs, although specific names are not provided. The company has achieved significant milestones in demonstrating the efficacy and safety of its therapeutics, particularly with Tafamidis. Protego Biopharma's impact lies in its innovative approach to addressing protein misfolding diseases, potentially offering new hope for patients with these challenging conditions.